Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000060309

Apexbio Technology LLC Regorafenib hydrochloride(Synonyms: Regorafenib HCl, BAY 73-4506, Stivarga, BAY73-4506 hydrochloride, Regorafenib hydrochloride salt), 10mM (in 1mL DMSO), CAS: 835621-07-3.
SDP

Catalog No. 5000060309
Encompass_Preferred

Regorafenib hydrochloride (CAS 835621-07-3) is an orally bioavailable small molecule inhibitor targeting multiple protein kinases including c-KIT VEGFR2 and B-Raf It inhibits these kinases with IC50 values of approximately 17 nM (c-KIT) 40 nM (VEGFR2) and 69 nM (B-Raf) By blocking kinase signaling Regorafenib hydrochloride effectively interrupts tumor-associated pathways involved in cell proliferation angiogenesis and survival It is widely used in oncology research for studies focused on kinase-mediated tumor growth and vascularization mechanisms

Catalog No. 50-000-60309 Supplier Apexbio Technology LLC Supplier No. A37505.1
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Regorafenib hydrochloride (CAS 835621-07-3) is an orally bioavailable small molecule inhibitor targeting multiple protein kinases including c-KIT VEGFR2 and B-Raf It inhibits these kinases with IC50 values of approximately 17 nM (c-KIT) 40 nM (VEGFR2) and 69 nM (B-Raf) By blocking kinase signaling Regorafenib hydrochloride effectively interrupts tumor-associated pathways involved in cell proliferation angiogenesis and survival It is widely used in oncology research for studies focused on kinase-mediated tumor growth and vascularization mechanisms

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.